On May 20, Haixi New Drug (02637.HK) rose 5.37% in regular trading, trading at 248.2 HKD/share, with trading volume of approximately 28.97 million HKD. The stock extended its rebound after fully digesting profit-taking pressure during the May 13-15 pullback.

On the news front, the company's annual report showed revenue of RMB 5.82 billion, up 24.79% year-over-year, with net profit attributable to shareholders reaching RMB 1.77 billion, a 30.09% increase. Gross margin improved to 83.38%. Multiple brokerages including Guohai Securities, Huayuan Securities, and Shenwan Hongyuan initiated or maintained Buy ratings, with target prices ranging from 298 to 339 HKD, implying significant upside from current levels.

Notably, the broader Pharmaceuticals sector traded weak on the day, with CSPC Pharma down 1.48%, Hansoh Pharma down 1.65%, Hengrui Pharma down 0.65%, and Simcere Pharma down 5.27%, highlighting the stock's relative outperformance against sector headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)